| Budget Amount *help |
¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2019: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2018: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2017: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Bone marrow-derived mesenchymal stem/progenitor cells (MSCs) were focused on the suppression of tissue damages including central nervous system as well as the multipotency. The present project is to demonstrate the cross-talking between human MSCs (hMSCs) and the recipient mouse cells in vivo and in vitro.
hMSCs responded to ischemic/neuronal cell damaging homogenate, in particular, the inflammatory cytokines. It was reproduced transplanted hMSCs after ischemia and the hMSCs might mainly respond to macrophages. Transplanted hMSCs decreased spinal cord injury. The hMSCs increased CCL5 expression and the CCL5 contributed to macrophages/microglia polarization and axonal extension.
|
